These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 22359263)

  • 1. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.
    Pollack SM; Jungbluth AA; Hoch BL; Farrar EA; Bleakley M; Schneider DJ; Loggers ET; Rodler E; Eary JF; Conrad EU; Jones RL; Yee C
    Cancer; 2012 Sep; 118(18):4564-70. PubMed ID: 22359263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy.
    Kohli K; Yao L; Nowicki TS; Zhang S; Black RG; Schroeder BA; Farrar EA; Cao J; Sloan H; Stief D; Cranmer LD; Wagner MJ; Hawkins DS; Pillarisetty VG; Ribas A; Campbell J; Pierce RH; Kim EY; Jones RL; Riddell SR; Yee C; Pollack SM
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms.
    Hemminger JA; Iwenofu OH
    Mod Pathol; 2013 Sep; 26(9):1204-10. PubMed ID: 23599152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.
    Pollack SM
    Expert Rev Vaccines; 2018 Feb; 17(2):107-114. PubMed ID: 29280411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pathological significance of NY-ESO-1 expression in the diagnosis of myxoid liposarcoma].
    Hei SM; Wei HJ; Chen H; Wang JG
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):225-230. PubMed ID: 30831650
    [No Abstract]   [Full Text] [Related]  

  • 6. The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas.
    Hemminger JA; Ewart Toland A; Scharschmidt TJ; Mayerson JL; Kraybill WG; Guttridge DC; Iwenofu OH
    Mod Pathol; 2013 Feb; 26(2):282-8. PubMed ID: 22936067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma.
    Shurell E; Vergara-Lluri ME; Li Y; Crompton JG; Singh A; Bernthal N; Wu H; Eilber FC; Dry SM
    Oncotarget; 2016 Nov; 7(45):72860-72867. PubMed ID: 27655679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma.
    Iura K; Kohashi K; Hotokebuchi Y; Ishii T; Maekawa A; Yamada Y; Yamamoto H; Iwamoto Y; Oda Y
    J Pathol Clin Res; 2015 Jul; 1(3):144-59. PubMed ID: 27499900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1.
    Iura K; Kohashi K; Ishii T; Maekawa A; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Matsumoto Y; Iwamoto Y; Oda Y
    Virchows Arch; 2017 Sep; 471(3):383-392. PubMed ID: 28744588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
    Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
    Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
    Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
    Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
    Rodolfo M; Luksch R; Stockert E; Chen YT; Collini P; Ranzani T; Lombardo C; Dalerba P; Rivoltini L; Arienti F; Fossati-Bellani F; Old LJ; Parmiani G; Castelli C
    Cancer Res; 2003 Oct; 63(20):6948-55. PubMed ID: 14583496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.
    Pollack SM; Li Y; Blaisdell MJ; Farrar EA; Chou J; Hoch BL; Loggers ET; Rodler E; Eary JF; Conrad EU; Jones RL; Yee C
    PLoS One; 2012; 7(2):e32165. PubMed ID: 22384167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.
    Sharma P; Gnjatic S; Jungbluth AA; Williamson B; Herr H; Stockert E; Dalbagni G; Donat SM; Reuter VE; Santiago D; Chen YT; Bajorin DF; Old LJ
    Cancer Immun; 2003 Dec; 3():19. PubMed ID: 14680360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
    Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
    PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.
    Lai JP; Robbins PF; Raffeld M; Aung PP; Tsokos M; Rosenberg SA; Miettinen MM; Lee CC
    Mod Pathol; 2012 Jun; 25(6):854-8. PubMed ID: 22388761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system.
    Jakka G; Schuberth PC; Thiel M; Held G; Stenner F; Van Den Broek M; Renner C; Mischo A; Petrausch U
    Anticancer Res; 2013 Oct; 33(10):4189-201. PubMed ID: 24122982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
    Ramachandran I; Lowther DE; Dryer-Minnerly R; Wang R; Fayngerts S; Nunez D; Betts G; Bath N; Tipping AJ; Melchiori L; Navenot JM; Glod J; Mackall CL; D'Angelo SP; Araujo DM; Chow WA; Demetri GD; Druta M; Van Tine BA; Grupp SA; Abdul Razak AR; Wilky B; Iyengar M; Trivedi T; Winkle EV; Chagin K; Amado R; Binder GK; Basu S
    J Immunother Cancer; 2019 Oct; 7(1):276. PubMed ID: 31651363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.
    Yuan J; Adamow M; Ginsberg BA; Rasalan TS; Ritter E; Gallardo HF; Xu Y; Pogoriler E; Terzulli SL; Kuk D; Panageas KS; Ritter G; Sznol M; Halaban R; Jungbluth AA; Allison JP; Old LJ; Wolchok JD; Gnjatic S
    Proc Natl Acad Sci U S A; 2011 Oct; 108(40):16723-8. PubMed ID: 21933959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
    Maraskovsky E; Sjölander S; Drane DP; Schnurr M; Le TT; Mateo L; Luft T; Masterman KA; Tai TY; Chen Q; Green S; Sjölander A; Pearse MJ; Lemonnier FA; Chen W; Cebon J; Suhrbier A
    Clin Cancer Res; 2004 Apr; 10(8):2879-90. PubMed ID: 15102697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.